Henovcom
Guangzhou Henovcom Bioscience Co., Ltd., founded in 2013 in Guangzhou, China by biopharmaceutical experts from GILEAD, Pfizer, Novartis, specializes in the discovery, development, and commercialization of innovative therapeutics and products to address global unmet medical needs in therapeutic areas including antiviral, anti-fibrotic, inflammation, and CNS. Four NMEs are currently in clinical development in the US and China. Henovcom has filed over 70 patents worldwide.
The company boasts a dedicated R&D team and efficient drug discovery and development platforms, including medicinal chemistry, API process development, and clinical operation.
Leveraging its extensive experience in nucleoside modifications and nucleic acid chemistry, Henovcom has developed a novel and highly efficient mRNA capping technology for “one-pot” IVT of mRNA and the proprietary capping agent LZCap®, as well as various modified nucleotides for mRNA synthesis on both research and commercial scales. Henovcom has established a state-of-the-art GMP facility to produce LZCap® and other nucleotides.
